Does patient age influence anti-cancer immunity?

Area of Science:

• Geriatric oncology
• Immunology
• Cancer immunotherapy

Background:

• Geriatric oncology traditionally focused on chemotherapy tolerance.
• Immunosenescence, or immune system aging, is critical for new immunotherapies.
• Concerns exist about elderly immune function impacting anti-cancer immunity.

Purpose of the Study:

• To contrast immune features in elderly versus young individuals (immunosenescence).
• To examine the influence of patient age on outcomes with immune checkpoint blockade therapy.
• To highlight the need for age-specific considerations in clinical trial design for cancer immunotherapies.

Main Methods:

• Review and contrast of immune system characteristics in elderly and young populations.
• Analysis of existing clinical data on elderly patients receiving immune checkpoint inhibitors.
• Discussion of age-related changes in T cell populations and suppressive cells.

Main Results:

• Elderly immune systems show reduced naive T cells and potential T cell exhaustion.
• Anecdotal clinical evidence suggests comparable responses and toxicity in elderly patients treated with anti-CTLA-4 or anti-PD-1/PD-L1 antibodies.
• Advanced age does not appear to negatively impact responses to these immunotherapies.

Conclusions:

• Immunosenescence presents unique challenges and considerations for cancer immunotherapy in the elderly.
• Current anecdotal evidence is encouraging regarding the efficacy and safety of checkpoint inhibitors in older adults.
• Future clinical trials must incorporate age as a critical factor to optimize cancer treatment strategies for geriatric patients.